MK-7684A: Primary completion of P3 KeyVibe007 trial (NCT05226598) for 1L mNSCLC in 2025 (Merck (MSD)) - Jun 7, 2022 - ASCO 2022: Primary completion of P3 KeyVibe008 trial (NCT05224141) for extensive-stage SCLC in 2025
Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer
|